Glycoside Hydrolases [CS] class drugs

12 results
  • darzalex faspro - daratumumab and hyaluronidase - fihj

    (Daratumumab And Hyaluronidase-Fihj (Human Recombinant))
    Janssen Biotech, Inc.
    DARZALEX FASPRO treats adult patients with multiple myeloma (newly diagnosed or relapsed/refractory, across various combination regimens), high-risk smoldering multiple myeloma, and newly diagnosed light chain (AL) amyloidosis. Not recommended for AL amyloidosis with NYHA Class IIIB/IV cardiac disease outside clinical trials.
  • herceptin hylecta - trastuzumab and hyaluronidase - oysk injection, solution

    (Trastuzumab And Hyaluronidase-Oysk)
    Genentech, Inc.
    Herceptin Hylecta (trastuzumab/hyaluronidase) treats HER2-overexpressing breast cancer in adults. Indicated for adjuvant treatment of node-positive or high-risk node-negative breast cancer, and for metastatic breast cancer — first-line with paclitaxel or as a single agent after prior chemotherapy.
  • phesgo - pertuzumab, trastuzumab, and hyaluronidase - zzxf injection, solution

    (Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf)
    Genentech, Inc.
    Phesgo (pertuzumab, trastuzumab, hyaluronidase) treats HER2-positive breast cancer in adults: neoadjuvant and adjuvant treatment with chemotherapy for early-stage breast cancer, and with docetaxel for metastatic breast cancer in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
  • rituxan hycela - rituximab and hyaluronidase injection, solution

    (Rituximab And Hyaluronidase)
    Genentech, Inc.
    Rituxan Hycela treats adult patients with follicular lymphoma (relapsed/refractory, previously untreated, or non-progressing after CVP), previously untreated diffuse large B-cell lymphoma with chemotherapy, and previously untreated or treated chronic lymphocytic leukemia with fludarabine and cyclophosphamide. Requires prior IV rituximab dose.